Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier:
NCT00661713
First received: April 16, 2008
Last updated: June 26, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2010
  Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
No publications provided by Novartis

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):